The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura

Transfus Apher Sci. 2012 Jun;46(3):343-6. doi: 10.1016/j.transci.2012.03.027. Epub 2012 Apr 3.

Abstract

The Phase II TITAN trial is designed to assess the efficacy and safety of an anti-von Willebrand factor (vWF) Nanobody in patients with acquired thrombotic thrombocytopenic purpura (TTP). Nanobodies are a novel class of therapeutic proteins and are based on the smallest functional fragments of single-chain antibodies that occur naturally in the Camelidae family (Nanobody® and Nanobodies® are registered trademarks of Ablynx NV). With vWF implicated in the thrombotic process underlying TTP, an anti-vWF Nanobody may hold significant promise as adjunctive therapy to plasma exchange. Recruitment is currently ongoing, and aims to include a total of 110 patients from countries in Europe, the Middle East, Australia and Northern America.

Trial registration: ClinicalTrials.gov NCT01151423.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Camelids, New World
  • Female
  • Humans
  • Male
  • Plasma Exchange*
  • Purpura, Thrombotic Thrombocytopenic / therapy*
  • Single-Chain Antibodies / administration & dosage*
  • Single-Chain Antibodies / adverse effects
  • von Willebrand Factor / antagonists & inhibitors*

Substances

  • Single-Chain Antibodies
  • von Willebrand Factor

Associated data

  • ClinicalTrials.gov/NCT01151423